Cushing's Syndrome (CS) Market Insights, Epidemiology and Market Forecast-2027

DelveInsight Business Research LLP


Albany, NY -- (SBWIRE) -- 10/05/2018 -- DelveInsight has announced the addition of the "Cushing's Syndrome (CS) Market Insights, Epidemiology and Market Forecast-2027" to their offering.

DelveInsight's "Cushing's Syndrome - Market Insights, Epidemiology & Market Forecast-2027" Report provides an overview of the disease and market size of Cushing's Syndrome for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Cushing's syndrome forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Cushing's Syndrome (CS), also known as hypercortisolism, is a rare disorder, which refers to the clinical manifestations induced by chronic exposure to excess glucocorticoids and may have exogenous or endogenous origin. Exogenous CS is due to the intake of anti-inflammatory steroid medications, ritonavir co-administration in HIV-infected patients or high-dose megestrol. Endogenous CS may be either corticotropin (ACTH)-dependent or -independent. ACTH dependent CS is found in 75-80% of the patient population and remaining patients have ACTH-independent CS.

The prevalence of endogenous Cushing's Syndrome (CS) is 1/26,000 and, in the EU, it has an annual incidence of 1/1,400,000-1/400,000, with a peak incidence at 25-40 years of age. As per the National Organization for Rare Disorders, although it may occur in children, Cushing's syndrome most commonly affects adults between the ages of 25 to 40. As per the study published by Broder et al, in 2015, the incidence of the Cushing's disease may be 5 to 25 per million per year. However, the reported incidence was much lower (1.2 to 2.4 per million per year) in one population-based study. In the United States study, the incidence was higher than previously reported in European studies, as it was found to affect 6.2 to 7.6 per million person-years.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Cushing's Syndrome Drug Companies

1. Corcept Therapeutics
2. Millendo Therapeutics
3. Novartis
4. Cortendo

And many others

Drugs covered

1. CORT125134
2. COR-003
3. Metyrapone

And many others

Report Scope

The report covers a descriptive overview of the Cushing's Syndrome, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Cushing's Syndrome and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Cushing's Syndrome are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Cushing's Syndrome market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cushing's Syndrome market.